WuXi Biologics sells its vaccine plant in Ireland to Merck for 500 million euros

A strategic transaction that strengthens WuXi's global impact

Despite a challenging market environment marked by regulatory changes and geopolitical challenges, WuXi Biologics—a company included in the Vintage Altaroc Odyssey —continues to demonstrate its resilience and commitment to innovation. The Dundalk facility, the result of an initial investment of 200 million euros, served as a model for integrated vaccine production. The decision to sell this site to Merck stems from a clear vision: to refocus its efforts on strategic, high-value-added projects and maximize the overall impact of its operations.

Merck, which already operated the site via a 20-year contract to manufacture vaccines generating $150 million in annual revenues, was the natural partner for this acquisition. This transaction illustrates not only the quality of WuXi's infrastructure and expertise, but also its ability to collaborate with major industry players.

WuXi Biologics: a forward-looking trajectory

The sale of the Dundalk site is part of WuXi Biologics' proactive strategy to optimize its resources in response to market developments and emerging opportunities. With ongoing investment in innovation and a strong portfolio of assets, the company continues to reinforce its position as a world leader in biologics manufacturing.